Neutrophil-Derived Microvesicles: Tiny Messengers in Your Body's Immune Chat
"Unlocking the Secrets of How These Microvesicles Mediate Inflammation and Impact Disease"
When your body faces infection or injury, a precisely controlled inflammatory response is crucial to fight off invaders and minimize harm to your own tissues. White blood cells, or leukocytes, are essential players in this process, acting as first responders that can later become less responsive or even undergo programmed cell death (apoptosis).
Intriguingly, leukocytes, at various stages from activation to apoptosis, release tiny vesicles called microvesicles (MVs). Ranging in size from 0.1 to 1.0 micrometer, these vesicles carry proteins, RNA, and DNA from their parent cells. Neutrophil-derived microvesicles (NDMVs), in particular, are found to increase significantly under inflammatory conditions.
This article explores the current research on NDMVs, detailing the conditions in which they increase, the mechanisms behind their formation, and how they affect other cells in the body. Understanding NDMVs better could lead to new diagnostic tools and therapies for infections and injuries.
Microvesicles as Inflammation Modulators
Neutrophils release microvesicles when activated, even though activated neutrophils themselves are primarily involved in acute inflammation. The microvesicles they produce are described as largely anti-inflammatory, and one study examined their effects on proinflammatory cytokines in tumor necrosis factor α (TNFα)-stimulated fibroblast-like cells. A 2021 review discusses neutrophil microvesicles and their possible role in cardiovascular disease. These sources describe emerging biological effects and research directions rather than an established clinical approach.
From First Responders to Vesicle Research
Neutrophils are characterized as first responders to infectious and inflammatory stimuli, with bone marrow production, migration, and activity maturing rapidly. Their interaction with vascular endothelial cells in cardiovascular inflammation has been known for many years, and the receptors involved are described as well characterized. More recent work frames neutrophil-released microvesicles as part of anti-inflammatory reprogramming. The broader history of extracellular-vesicle research is multidisciplinary; focusing only on Peter Wolf’s “platelet dust” and Johnstone’s work on vesicles from maturing red blood cells can make it seem to have begun as a straight line in blood science.
When Do NDMVs Show Up? Increased Numbers in Disease States
Under normal, healthy conditions, NDMVs are present in the body in very small numbers. However, their levels rise significantly in various inflammatory disorders, suggesting they play a role in these conditions.
- Cardiovascular Disease/Atherosclerosis: Elevated levels suggest a link between NDMVs and the progression of atherosclerosis.
- Systemic Lupus Erythematosus, Anti-phospholipid Syndrome: Increased NDMVs are associated with these autoimmune conditions affecting blood vessels.
- ANCA-associated vasculitis: NDMVs contribute to inflammation of blood vessels in this condition.
- Pneumonia/ARDS: Higher NDMV levels are found in lung fluid samples from patients with pneumonia and ARDS (Acute Respiratory Distress Syndrome).
- Tubulo-interstitial nephritis, Vasculitis, IgA Nephropathy: Patients with these kidney disorders show increased NDMV populations.
- Sepsis: Both in blood and at sites of infection (peritoneal lavage), NDMVs are elevated.
- Localized Infection: Higher concentrations of NDMVs are found at the site of infection, such as in blister fluid.
Vesicles in Immune Communication and Resolution
Reviews report that neutrophils and monocytes can release microvesicles and exosomes, which may act on the releasing cell or communicate with other cells. In cystic fibrosis research, polymorphonuclear-neutrophil-derived microvesicles have also been reported to modulate the function of other immune cells. A 2025 report on Hsu et al.’s study in Cell describes complement-inhibiting vesicles released as neutrophils age as a self-resolving, anti-inflammatory mechanism that supports a return to homeostasis. Research on neutrophil-driven injury after myocardial infarction also highlights the importance of innate immune cells beyond the acute phase.
The Future of NDMV Research: New Avenues for Treatment?
The field of NDMVs is still relatively new, with many questions remaining. The impact of these microvesicles on the body's inflammatory response highlights the need for more research in this area.
Microvesicles as Potential Therapeutic Tools
A 2018 study examined whether neutrophil-derived microvesicles could alter target-cell behavior, focusing on macrophages and comparing microvesicles from healthy controls and people with rheumatoid arthritis. The source describes microvesicles as an emerging means of cell-to-cell communication in inflammation. A separate study summary, dated January 26, 2026, reports an immunostimulation method for producing anti-inflammatory microvesicles and proposes a microRNA-based system for joint-related diseases, including osteoarthritis. It identifies cartilage penetration and metabolic homeostasis among the system’s research themes, while describing the approach as a potential treatment rather than an established therapy.
NDMVs hold promise as biomarkers for disease and as targets for medical intervention. A standardized method for qualifying and quantifying NDMVs is essential.
Further research to clarify the molecular mechanisms of NDMV generation and their effects on target cells, understanding the effects of NDMVs and target cells, and identifying molecular targets involved in NDMV generation, the clinician will potentially be able to modulate the immune system through control of NDMV production.